Clinical Value of ctDNA in Hematological Malignancies (Lymphomas, Multiple Myeloma, Myelodysplastic Syndrome, and Leukemia): A Meta-Analysis
Background: Circulating tumor DNA (ctDNA) has offered a minimally invasive approach for the detection and measurement of cancer. However, its diagnostic and prognostic value in hematological malignancies remains unclear.Materials and methods: Pubmed, Embase, and Cochrane Library were searched for re...
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2021-03-01
|
| Series: | Frontiers in Oncology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fonc.2021.632910/full |
| _version_ | 1818827407487926272 |
|---|---|
| author | Xiangyu Tan Han Yan Lei Chen Yuyang Zhang Chunyan Sun Chunyan Sun |
| author_facet | Xiangyu Tan Han Yan Lei Chen Yuyang Zhang Chunyan Sun Chunyan Sun |
| author_sort | Xiangyu Tan |
| collection | DOAJ |
| description | Background: Circulating tumor DNA (ctDNA) has offered a minimally invasive approach for the detection and measurement of cancer. However, its diagnostic and prognostic value in hematological malignancies remains unclear.Materials and methods: Pubmed, Embase, and Cochrane Library were searched for relating literature. Diagnostic accuracy variables and disease progression prediction data were pooled by the Meta-Disc version 1.4 software. Review Manager version 5.4 software was applied for prognostic data analysis.Results: A total of 11 studies met our inclusion criteria. In terms of diagnosis, the pooled sensitivity and specificity were 0.51 (95% confidence intervals (CI) 0.38–0.64) and 0.96 (95% CI 0.88–1.00), respectively. The AUSROC (area under the SROC) curve was 0.89 (95%CI 0.75–1.03). When it comes to the prediction of disease progression, the overall sensitivity and specificity was 0.83 (95% CI 0.67–0.94) and 0.98 (95% CI 0.93–1.00), respectively. Moreover, a significant association also existed between the presence of ctDNA and worse progression-free survival (HR 2.63, 95% CI 1.27–5.43, p = 0.009), as well as overall survival (HR 2.92, 95% CI 1.53–5.57, p = 0.001).Conclusions: The use of ctDNA in clinical practice for hematological malignancies is promising, as it may not only contribute to diagnosis, but could also predict the prognosis of patients so as to guide treatment. In the future, more studies are needed to realize the standardization of sequencing techniques and improve the detection sensitivity of exploration methods. |
| first_indexed | 2024-12-19T00:43:04Z |
| format | Article |
| id | doaj.art-b896ebb164de4edeb18039ad2a142331 |
| institution | Directory Open Access Journal |
| issn | 2234-943X |
| language | English |
| last_indexed | 2024-12-19T00:43:04Z |
| publishDate | 2021-03-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Oncology |
| spelling | doaj.art-b896ebb164de4edeb18039ad2a1423312022-12-21T20:44:26ZengFrontiers Media S.A.Frontiers in Oncology2234-943X2021-03-011110.3389/fonc.2021.632910632910Clinical Value of ctDNA in Hematological Malignancies (Lymphomas, Multiple Myeloma, Myelodysplastic Syndrome, and Leukemia): A Meta-AnalysisXiangyu Tan0Han Yan1Lei Chen2Yuyang Zhang3Chunyan Sun4Chunyan Sun5Department of Hematology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, ChinaDepartment of Hematology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, ChinaDepartment of Hematology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, ChinaDepartment of Hematology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, ChinaDepartment of Hematology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, ChinaCollaborative Innovation Center of Hematology, Huazhong University of Science and Technology, Wuhan, ChinaBackground: Circulating tumor DNA (ctDNA) has offered a minimally invasive approach for the detection and measurement of cancer. However, its diagnostic and prognostic value in hematological malignancies remains unclear.Materials and methods: Pubmed, Embase, and Cochrane Library were searched for relating literature. Diagnostic accuracy variables and disease progression prediction data were pooled by the Meta-Disc version 1.4 software. Review Manager version 5.4 software was applied for prognostic data analysis.Results: A total of 11 studies met our inclusion criteria. In terms of diagnosis, the pooled sensitivity and specificity were 0.51 (95% confidence intervals (CI) 0.38–0.64) and 0.96 (95% CI 0.88–1.00), respectively. The AUSROC (area under the SROC) curve was 0.89 (95%CI 0.75–1.03). When it comes to the prediction of disease progression, the overall sensitivity and specificity was 0.83 (95% CI 0.67–0.94) and 0.98 (95% CI 0.93–1.00), respectively. Moreover, a significant association also existed between the presence of ctDNA and worse progression-free survival (HR 2.63, 95% CI 1.27–5.43, p = 0.009), as well as overall survival (HR 2.92, 95% CI 1.53–5.57, p = 0.001).Conclusions: The use of ctDNA in clinical practice for hematological malignancies is promising, as it may not only contribute to diagnosis, but could also predict the prognosis of patients so as to guide treatment. In the future, more studies are needed to realize the standardization of sequencing techniques and improve the detection sensitivity of exploration methods.https://www.frontiersin.org/articles/10.3389/fonc.2021.632910/fullcirculating tumor DNAhematological malignancieslymphomasmultiple myelomamyelodysplastic syndromeleukemia |
| spellingShingle | Xiangyu Tan Han Yan Lei Chen Yuyang Zhang Chunyan Sun Chunyan Sun Clinical Value of ctDNA in Hematological Malignancies (Lymphomas, Multiple Myeloma, Myelodysplastic Syndrome, and Leukemia): A Meta-Analysis Frontiers in Oncology circulating tumor DNA hematological malignancies lymphomas multiple myeloma myelodysplastic syndrome leukemia |
| title | Clinical Value of ctDNA in Hematological Malignancies (Lymphomas, Multiple Myeloma, Myelodysplastic Syndrome, and Leukemia): A Meta-Analysis |
| title_full | Clinical Value of ctDNA in Hematological Malignancies (Lymphomas, Multiple Myeloma, Myelodysplastic Syndrome, and Leukemia): A Meta-Analysis |
| title_fullStr | Clinical Value of ctDNA in Hematological Malignancies (Lymphomas, Multiple Myeloma, Myelodysplastic Syndrome, and Leukemia): A Meta-Analysis |
| title_full_unstemmed | Clinical Value of ctDNA in Hematological Malignancies (Lymphomas, Multiple Myeloma, Myelodysplastic Syndrome, and Leukemia): A Meta-Analysis |
| title_short | Clinical Value of ctDNA in Hematological Malignancies (Lymphomas, Multiple Myeloma, Myelodysplastic Syndrome, and Leukemia): A Meta-Analysis |
| title_sort | clinical value of ctdna in hematological malignancies lymphomas multiple myeloma myelodysplastic syndrome and leukemia a meta analysis |
| topic | circulating tumor DNA hematological malignancies lymphomas multiple myeloma myelodysplastic syndrome leukemia |
| url | https://www.frontiersin.org/articles/10.3389/fonc.2021.632910/full |
| work_keys_str_mv | AT xiangyutan clinicalvalueofctdnainhematologicalmalignancieslymphomasmultiplemyelomamyelodysplasticsyndromeandleukemiaametaanalysis AT hanyan clinicalvalueofctdnainhematologicalmalignancieslymphomasmultiplemyelomamyelodysplasticsyndromeandleukemiaametaanalysis AT leichen clinicalvalueofctdnainhematologicalmalignancieslymphomasmultiplemyelomamyelodysplasticsyndromeandleukemiaametaanalysis AT yuyangzhang clinicalvalueofctdnainhematologicalmalignancieslymphomasmultiplemyelomamyelodysplasticsyndromeandleukemiaametaanalysis AT chunyansun clinicalvalueofctdnainhematologicalmalignancieslymphomasmultiplemyelomamyelodysplasticsyndromeandleukemiaametaanalysis AT chunyansun clinicalvalueofctdnainhematologicalmalignancieslymphomasmultiplemyelomamyelodysplasticsyndromeandleukemiaametaanalysis |